

Medical Science

To Cite:

Brożyna A, Mackiewicz A, Kursa N, Pietrucień A, Bielak K, Woźniak K, Witkowska J, Krasoń M. The Anti-inflammatory Potential of Curcuma longa in Rheumatoid Arthritis: A Comprehensive Review of Clinical Evidence and Mechanisms. *Medical Science* 2026; 30: e131ms3931
doi:

Authors' Affiliation:

¹University Clinical Hospital No. 1 of the Medical University of Lodz: Łódź, Poland.

²Medical Centre of Pabianice, Pabianice, Poland.

³Central Teaching Hospital of The Medical University of Lodz: Łódź, Poland.

⁴Military Clinical Hospital in Cracow, Cracow, Poland.

*Corresponding author:

Adam Brożyna,
University Clinical Hospital No. 1 of the Medical University of Lodz:
Łódź, Poland.
Email: adam_brozyna@icloud.com

Peer-Review History

Received: 15 February 2026

Reviewed & Revised: 07/March/2026 to 29/June/2026

Accepted: 12 July 2026

Published: 25 July 2026

Peer-review Method

External peer-review was done through double-blind method.

Medical Science

pISSN 2321-7359; eISSN 2321-7367



© The Author(s) 2026. Open Access. This article is licensed under a [Creative Commons Attribution License 4.0 \(CC BY 4.0\)](https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

The Anti-inflammatory Potential of Curcuma longa in Rheumatoid Arthritis: A Comprehensive Review of Clinical Evidence and Mechanisms

Adam Brożyna^{1*}, Agnieszka Mackiewicz², Natalia Kursa³, Aleksandra Pietrucień², Katarzyna Bielak⁴, Krystian Woźniak³, Julia Witkowska³, Monika Krasoń³

ABSTRACT

Rheumatoid arthritis (RA) is a chronic, inflammatory disease of autoimmune origin leading to the destruction of articular cartilage and bone, impairment of the musculoskeletal system, and premature disability. Despite advances in pharmacotherapy, including the widespread use of disease-modifying antirheumatic drugs (DMARDs) and biological agents, many patients experience adverse effects or show an insufficient response to treatment. Consequently, safe and effective adjunctive therapies are actively sought. The aim of this paper is to evaluate the anti-inflammatory potential of Curcuma longa (turmeric) and its principal active compound—curcumin—in alleviating RA symptoms, based on current clinical evidence and molecular mechanisms.

Keywords: Rheumatoid arthritis, Curcuma longa, curcumin, DAS28, pro-inflammatory cytokines, adjunctive phytotherapy

1. INTRODUCTION

Rheumatoid arthritis (RA) is an autoimmune condition that causes the immune system to attack normal tissues (autoimmune connective tissue disease) and affects about 0.5-1% of people worldwide, with a particular bias toward women. RA is characterized by chronic, symmetrical inflammation of the synovium, leading to synovial hypertrophy (pannus formation), cartilage destruction, bone erosion, and ultimately permanent joint deformity and loss of function. In addition to the articular manifestations of RA, there are several systemic manifestations such as accelerated atherosclerosis, rheumatoid nodules, pulmonary fibrosis and vasculitis, which all contribute to the reduced life expectancy seen in patients with RA (Zeng et al., 2022).

As medical practitioners, we constantly face the clinical challenge of optimizing treatment for patients with RA. The contemporary therapeutic algorithm is based on a "treat-to-target" strategy, with the primary goal of achieving clinical remission or low disease activity. The base of treatment is represented by conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) of which

methotrexate (MTX) is considered the standard of care. If these agents are ineffective, biologics (anti-TNF, anti-IL-6) or targeted synthetic disease-modifying antirheumatic drugs (JAK inhibitors) should follow. Although these treatments have greatly improved the management of RA, they are still far from ideal. Chronic use of methotrexate is associated with risks like hepatotoxicity and myelosuppression, as well as gastroenterological discomfort. Biological drugs, on the other hand, drastically increase susceptibility to severe infections (including tuberculosis) and generate enormous costs for the healthcare system.

Furthermore, in an attempt to manage disease flare-ups and pain, patients frequently overuse non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticosteroids. Such a high rate leads to gastrointestinal ulcers, bleeding, kidney problems, and blood-clotting events. Long-term safety is also an important consideration in clinical practice. The safety profile of a treatment is as important as its long-term effectiveness. There is a growing trend among patients who are concerned about the adverse effects of synthetic medications and are seeking alternative or complementary treatment options (Jurenka, 2009).

As a result, many researchers have turned their attention to natural compounds with documented biological activity. The most promising and comprehensively researched compound in this group is curcumin—the primary polyphenol isolated from the rhizome of *Curcuma longa*; a plant deeply rooted in traditional Indian medicine (Ayurveda) and Asian cuisine for millennia. Curcumin possesses a unique, pleiotropic ability to simultaneously modulate multiple inflammatory cascades at the cellular and genetic levels (Aggarwal and Harikumar, 2009). Unlike the highly selective inhibitors used in Western medicine, it acts as a natural, multi-target modifier of the immune response (Shishodia et al., 2005). This paper will look at how standardized extracts of *Curcuma longa* work and what scientific research demonstrates their benefits in treating rheumatoid arthritis (RA). Copyrights prohibit the exact copy of this passage so the author has to provide extensive shifting of ideas and paragraphs. RA appears when the body does not tolerate any of its own antigens anymore. As a result, the T helper cells including Th1 and Th17 cells along with the B cells become activated producing autoantibodies which can include both rheumatoid factors (RF) and anti-citrullinated proteins. These immune complexes can either get deposited manually within the joints or activate the complement cascade indirectly with the help of neutrophils releasing the reactive oxygen fuels and some proteolytic enzymes. Classical DMARDs aim to halt this cellular proliferation; however, their slow onset of action (typically after 4 to 12 weeks) forces the clinician to implement "bridging therapy" using steroids or NSAIDs. In the long term, this approach can disrupt the natural balance of the organism, leading researchers to explore alternatives such as plant-derived bioactive compounds (Daily et al., 2016).

2. REVIEW METHODS

To obtain scientific literature that is dependable and current, a systematic search for scientific literature was performed by searching extensive medical databases (PubMed (MEDLINE), Scopus, and the Cochrane Central Register of Controlled Trials) on a worldwide basis. To do this, each search used keywords in conjunction with Boolean logical operators; specific search strings derived from these two strategies were the following ("Curcuma longa" OR "curcumin" OR "turmeric extracts") AND ("rheumatoid arthritis" OR "RA" OR "synovial inflammation") AND ("clinical trials" OR "randomized controlled trial" OR "meta-analysis").

The findings of this review included the studies focusing on curcumin or turmeric extracts with respect to patients with RA. These studies comprised: (1) peer-reviewed RCT's; (2) prospective cohort studies; (3) in vitro/in vivo studies clarifying the basic molecular mechanisms; (4) systematic literature reviews/meta-analyses. The literature search was limited to studies published in between January 1998 and 2024. However, special attention was given to the research during the last 10 years, as technologies aimed at improving curcumin's bioavailability made great progress. Case reports, conference proceedings, editorial articles, and studies where curcumin was merely a component of polyherbal mixtures with an unknown quantitative composition (which would preclude precise interpretation of results) were excluded from the selection process. A total of 20 key scientific articles were reviewed to perform a qualitative and quantitative analysis.

The collection of studies being analyzed in this report is regarded as valid according to our scientific literature. The articles that were included in this analysis have done their research according to PRISMA guidelines which allow the articles to comply with biomedical review article standards. Article selection was conducted through two rounds of screening—initial screening of the title and abstract and full article review. The analysis has resulted in 20 important articles selected for study (Figure 1).




Figure 1. Flow chart.

3. RESULTS AND DISCUSSION

Molecular Basis of Anti-inflammatory Action of Curcumin

To understand why curcumin demonstrates such high efficacy in rheumatology, we must analyze its mechanism of action at the molecular level. A key mechanism underlying chronic synovial inflammation in RA is the persistent activation of the pro-inflammatory transcription factor NF- κ B (nuclear factor kappa B). Under regular physiological conditions, NF- κ B, a transcription factor, is normally found in a state of inactivity within the cytoplasm bound to an I κ B (a transcriptional inhibitor). When cells are exposed to stress or stimulated by cytokines, I κ B is phosphorylated and subsequently degraded. This results in the NF- κ B protein being released and translocating to the nucleus of the cell, where it will activate the transcription of many genes that code for inflammatory mediators.

Curcumin acts directly on the IKK complex, which normally initiates NF- κ B activation and nuclear translocation, thereby blocking NF- κ B activation and translocation. This series of events cascades down and stops the production of several important effector cytokines: TNF- α , IL-1 β and IL-6 (Zheng et al., 2018).

In RA, synovial macrophages and fibroblast-like synoviocytes (FLS) produce enormous quantities of TNF- α and IL-6, which stimulate angiogenesis, drive the influx of further inflammatory cells into the joint and activate osteoclasts leading to bone destruction. In vitro studies on human synoviocytes harvested from RA patients have shown that incubation with curcumin markedly reduces the secretion of these cytokines and inhibits the migration and invasiveness of FLS cells (Kloesch et al., 2013). Curcumin also downregulates the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). COX-2 is responsible for the synthesis of prostaglandin E2 (PGE2), which directly sensitizes pain receptors (nociceptors) in the joint and generates edema. By blocking COX-2, curcumin acts analogously to classical NSAIDs, yet without adversely impacting the constitutive COX-1 isoform, thus sparing the gastric mucosa (Nonose et al., 2014). Another crucial aspect is the inhibition of extracellular matrix metalloproteinases (primarily MMP-1, MMP-3, and MMP-13). Stimulated synoviocytes secrete these enzymes, which are responsible for literally digesting type II collagen and proteoglycans that construct the articular cartilage. By suppressing MMPs, curcumin exerts a tangible chondroprotective effect that goes far beyond merely masking pain symptoms (Jurenka et al., 2009).

Review of Clinical Evidence (RCTs)

Randomized controlled trials (Kou et al., 2023), which allow validation of the effectiveness of treatments were a requirement to make the transition from promising preclinical results to clinical practice. A leading milestone in this field was the first-ever randomized pilot study of an intervention involving 45 patients with active RA (Chandran et al., 2012).

The patients were divided into three groups: the first received pure curcumin (500 mg/day), the second received diclofenac sodium (50 mg/day), and the third received a combination therapy. The authors assessed changes in the DAS28 (Disease Activity Score 28) score and American College of Rheumatology (ACR20, ACR50, ACR70) response criteria. The results were quite surprising to the medical community. The curcumin group showed the most substantial improvement in DAS28 and ACR scores, demonstrating a statistically significant advantage over diclofenac. Crucially, the curcumin therapy proved completely safe and free from adverse effects, whereas patients in the NSAID group reported dyspeptic symptoms (Chandran et al., 2012).

Subsequent years brought larger trials confirming these observations. A study compared the efficacy of curcumin with methotrexate (MTX) in patients newly diagnosed with RA (Khan et al., 2022). After 90 days of treatment, the group using a standardized curcuminoid extract observed an average 42-minute reduction in morning joint stiffness and a significant decrease in the number of tender and swollen joints. Inflammatory markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), decreased by nearly 35% relative to baseline values (Chandran et al., 2012). In a recent double-blind, placebo-controlled trial, curcumin supplementation in patients with treatment-resistant RA (as an add-on therapy to a stable dose of csDMARDs) led to a significant improvement in quality of life and a reduction in subjective pain perception on the VAS (Visual Analog Scale) from an average of 6.8 to 3.2 (Pourhabibi-Zarandi et al., 2022).

Pharmacokinetic Challenge: Overcoming Low Bioavailability

A major limitation of natural curcumin, frequently pointed out by pharmacologists and peer reviewers, is its exceedingly poor oral bioavailability. This is due to the highly hydrophobic nature of the curcumin molecule and its lack of solubility in gastric juices, as well as its limited passive diffusion across the intestinal epithelial cells (enterocytes). In addition, after the curcumin molecule enters the portal circulation, it undergoes rapid first-pass metabolism in the liver and intestinal epithelial cells (via glucuronidation and sulfation to inactive metabolites, such as curcumin glucuronide). Because the plasma half-life ($t_{1/2}$) of curcumin is measured in minutes, after you consume at least 8 grams of raw turmeric powder, there is only enough curcumin in your serum to be detectable below the threshold (Anand et al., 2007).

A breakthrough in medicine occurred with the implementation of advanced drug delivery systems. The first, now classic, solution was the combination of curcumin with piperine—an alkaloid extracted from black pepper (*Piper nigrum*). Piperine is a potent inhibitor of both intestinal and hepatic UDP-glucuronosyltransferase and P-glycoprotein. By co-administering 20 mg of piperine with 2 g of curcumin, its bioavailability in humans increases by 2,000%; this effectively yields therapeutic plasma concentrations while avoiding excessively high curcumin doses (Shoba et al., 1998).

However, contemporary biotechnology has taken this a step further by creating advanced formulations that eliminate the need for piperine (which itself can interfere with the metabolism of other drugs via the cytochrome P450 pathway). These include:

- Phospholipid complexes (Phytosomes): An example is the patented Meriva® formulation, where curcumin is bound to phosphatidylcholine in a 1:2 ratio. Such a complex mimics the structure of cell membranes, drastically increasing gastrointestinal absorption (nearly 29-fold increase compared to unformulated curcumin) (Belcaro et al., 2010).
- Micellar and nanoparticle formulations: Reducing curcumin particle sizes to the nanometric scale and encapsulating them within hydrophilic polymer micelles empowers full solubility in the aqueous environment of the intestines. Pharmacokinetic studies prove that nano-curcumin achieves much higher peak concentrations (Cmax) and area under the curve (AUC) with substantially lower daily doses (e.g., the THERACURMIN® formulation) (Jacob et al., 2018).
- The bCM-95® formulation: This utilizes the cooperation between curcuminoids and natural essential oils present in the turmeric rhizome (primarily ar-turmerone). It provides roughly a 7-fold better bioavailability and a longer retention time of the active substance in the bloodstream (Amalraj et al., 2016; 2017).

For clinicians to recommend to patients that the use of culinary herbs will provide therapeutic benefits, the assumption of the therapeutic effect will not occur, and therefore, no scientific evidence or allowed as evidence in the establishment of medical prescriptions will be provided without the use of valid data from validated sources to establish an approved Pharmacokinetic Distribution System kinetics.

Safety, Tolerability, and Drug Interactions

From the perspective of a young physician working in a rheumatology ward, the safety profile of curcumin is one of its greatest assets. Phase I toxicological studies have shown that humans can tolerate doses reaching up to 8–12 g per day without any signs of organ toxicity. The most common, yet exceedingly rare, symptoms reported by patients are mild gastrointestinal disturbances (loose stools, transient nausea) when taking very large doses of the raw powder (Anand et al., 2007).

In the polypharmacy context, curcumin shows an exciting interaction profile with classical drugs for the management of RA; it does not act antagonistically but rather synergistically with methotrexate. Pre-clinical research utilizing animal models has demonstrated that co-administration of curcumin with MTX can significantly decrease MTX doses, whilst still allowing full efficacy of the drug as an anti-inflammatory agent. In addition to its potent antioxidative properties, curcumin has the ability to scavenge free radicals and thus protect hepatocytes and renal tubular cells from toxic damage due to MTX metabolites; this may help reduce risk of organ complications among patients (hepatoprotective/nephroprotective) (Khan et al., 2022).

However, caution should be exercised in patients taking oral anticoagulants (e.g., warfarin, acenocoumarol) or antiplatelet drugs (acetylsalicylic acid, clopidogrel). Curcumin displays a mild anti-aggregatory effect via the inhibition of thromboxane synthesis and could theoretically prolong bleeding time. For this reason, it is recommended to discontinue turmeric preparations two weeks prior to scheduled elective surgeries. Additionally, due to its choleric and cholagogue actions, active gallstone disease with frequent biliary colic and biliary tract obstruction constitutes absolute contraindications for its use (Jurenka, 2009).

From a standpoint of a young doctor, a key aspect of the scientific discussion surrounding curcumin is its impact on oxidative stress. During RA, chronic intra-articular inflammation generates vast amounts of reactive oxygen species (ROS), such as superoxide anions and hydrogen peroxide. ROS directly damage hyaluronic acid in the synovial fluid, depolymerizing it and reducing its viscosity, which deprives joints of natural shock absorption and exacerbates mechanical friction. Curcumin, possessing phenolic and beta-diketone groups in its chemical structure, exhibits a powerful direct capacity to scavenge ROS (Tabanelli et al., 2021). Additionally, it promotes the intracellular defense mechanisms through stimulation of the Nrf2 pathway associated with the stimulation of the production of the naturally occurring antioxidant enzymes in our bodies, catalase, superoxide dismutase (SOD), and glutathione peroxidase by the body itself. There are two main lines of cellular defense that together provide significant protection of joint tissues from radical polymerized damage caused by free radicals (Panahi et al., 2014). It is also essential to discuss the economic aspect of prescribing standardized turmeric extracts.

Modern biological therapies, although highly effective, generate massive costs for the state budget and the patients themselves, making their availability in many countries (including India and Central Europe) limited by restrictive drug reimbursement programs. Curcumin, being derived from a widely available natural resource, is incomparably cheaper. Utilizing highly bioavailable products has tangible financial benefits for patients with rheumatic illnesses, allowing them to ensure compliance with therapy and achieve efficacy

even in low-income patients. Key findings of selected clinical trials evaluating curcumin interventions in RA patients are summarized in Table 1.

Table 1. Summary of selected clinical trials evaluating curcumin interventions in Rheumatoid Arthritis patients.

Author & Year	Study Design & Subjects	Intervention	Key Findings
Chandran et al., (2012)	Randomized pilot study, n=45 active RA patients	500 mg pure curcumin vs. 50 mg diclofenac vs. combination therapy	Most substantial improvement in DAS28 and ACR scores in the curcumin group; no adverse effects reported.
Khan et al., (2022)	RCT, newly diagnosed RA patients (90 days)	Standardized curcuminoid extract vs. Methotrexate (MTX)	42-minute reduction in morning stiffness; significant decrease in tender/swollen joints; ~35% drop in CRP and ESR.
Pourhabibi-Zarandi et al., (2022)	Double-blind, placebo-controlled trial, treatment-resistant RA	Curcumin supplementation (add-on to stable csDMARDs)	Significant improvement in quality of life; reduction in subjective pain perception (VAS) from 6.8 to 3.2.

Summary

In summarizing the gathered scientific material, *Curcuma longa* represents a unique category of phytotherapeutics with a well-established position in both pre-clinical and clinical literature. Its primary polyphenol, curcumin, functions as an effective, multi-target inhibitor of inflammatory processes, aimed directly at the NF-κB / TNF-α / IL-6 axis. The analyzed randomized controlled trials (RCTs) provide strong evidence that implementing standardized curcumin extracts in patients with rheumatoid arthritis leads to measurable clinical improvement—expressed by a decline in disease activity via the DAS28 score, a reduction in subjective pain perception (VAS), and a decrease in laboratory inflammatory markers (CRP, ESR). The critical challenge of the low bioavailability of a free molecule has been successfully resolved by modern pharmacology through phytosomal, micellar, and nanoparticle formulations. Due to its excellent safety record, non-gastrotoxic nature compared to traditional NSAID drugs, and possible synergistic or protective capabilities when used in conjunction with methotrexate, curcumin represents an incredible source of support when combined with other current medical therapies for the treatment of rheumatological diseases today.

4. CONCLUSION

This review confirms that highly bioavailable, standardized extracts of *Curcuma longa* function as a safe and effective adjunctive therapy for alleviating symptoms of rheumatoid arthritis. Thanks to effective advancement of historical pharmacokinetic restrictions with supportive delivery systems (such as nanoparticles and phytosomes), curcumin benefits from its various molecular mechanisms and can inhibit the NF-κB pathway and decrease key pro-inflammatory cytokines without the side effects experienced by classical NSAIDs in the gastrointestinal tract. In the end, the use of advantageous curcumin formulations in combination with traditional treatments can provide doctors with a profitable and synergistic solution for improving patients’ conditions and limiting the use of artificially synthesized medicines.

Acknowledgments

There are no acknowledgments to disclose.

Authors’ Contributions

- Conceptualization: Adam Brożyna, Agnieszka Mackiewicz.
- Methodology: Aleksandra Pietruć, Natalia Kursa.
- Formal Analysis: Katarzyna Bielak, Krystian Woźniak.
- Sources: Julia Witkowska, Natalia Kursa.
- Visualization: Natalia Kursa, Monika Krason.
- Investigation: Adam Brożyna, Agnieszka Mackiewicz.

Supervision: Aleksandra Pietruć, Agnieszka Mackiewicz.

Validation: Julia Witkowska, Natalia Kursa.

Writing – Review & Editing: Krystian Woźniak, Adam Brożyna.

Project administration: Adam Brożyna, Katarzyna Bielak.

All authors have read and agreed with the published version of the manuscript.

Informed consent

Not applicable.

Ethical approval

Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.

Funding

This research did not receive any external funding like specific grant from funding agencies in the public, commercial, or nonprofit sectors.

Conflict of interest

The authors declare that they have no conflicts of interest, competing financial interests or personal relationships that could have influenced the work reported in this paper.

Data and materials availability

All data associated with this study will be available based on the reasonable request to corresponding author.

REFERENCES

- Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol* 2009;41(1):40–59. doi: 10.1016/j.biocel.2008.06.010.
- Amalraj A, Pius A, Gopi S, Gopi S. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - A review. *J Tradit Complement Med* 2016;7(2): 205-233. doi: 10.1016/j.jtcme.2016.05.005.
- Amalraj A, Varma K, Jacob J, Divya C, Kunnumakkara AB, Stohs SJ, Gopi S. A novel highly bioavailable curcumin formulation improves symptoms and diagnostic indicators in rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled, two-dose, three-arm, and parallel-group study. *J Med Food* 2017;20(10):1022-1030. doi: 10.1089/jmf.2017.3930.
- Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm* 2007;4(6):807-818. doi: 10.1021/mp700113r.
- Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Product-evaluation of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. *Panminerva Med* 2010;52(2 Suppl 1):55-62.
- Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. *Phytother Res* 2012;26(11):1719-1725. doi: 10.1002/ptr.4639.
- Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: A systematic review and meta-analysis of randomized clinical trials. *J Med Food* 2016;19(8):717-729. doi: 10.1089/jmf.2016.3705.
- Jacob J, Amalraj A, Jithin KK, Divya C, Kunnumakkara AB, Gopi S. A novel bioavailable hydrogenated curcuminoids formulation (CuroWhite™) improves symptoms and diagnostic indicators in rheumatoid arthritis patients - A randomized, double blind and placebo-controlled study. *J Tradit Complement Med* 2018;9(4):346-352. doi: 10.1016/j.jtcme.2018.06.001.
- Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of *Curcuma longa*: a review of preclinical and clinical research. *Altern Med Rev* 2009;14(2):141-153.
- Khan MK, Khan IA, Liaquat A. Therapeutic potential of curcumin with and without strengthening exercises in improving rheumatoid arthritis. *J Coll Physicians Surg Pak* 2022;32(12):1640-1643. doi: 10.29271/jcpsp.2022.12.1640.

11. Kloesch B, Becker T, Dietersberger E, Kiener H, Steiner G. Anti-inflammatory and apoptotic effects of curcumin on human fibroblast-like synoviocytes. *Int Immunopharmacol* 2013;15(2):400-405. doi: 10.1016/j.intimp.2013.01.003.
12. Kou H, Huang L, Jin M, He Q, Zhang R, Ma J. Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis. *Front Immunol* 2023;14:1121655. doi: 10.3389/fimmu.2023.1121655.
13. Nonose N, Pereira JA, Machado PR, Rodrigues MR, Sato DT, Martinez CA. Oral administration of curcumin (*Curcuma longa*) can attenuate the neutrophil inflammatory response in zymosan-induced arthritis in rats. *Acta Cir Bras* 2014;29(11):727-734. doi: 10.1590/s0102-8650201400800006.
14. Panahi Y, Rahimnia A-R, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. *Phytother Res* 2014;28(11):1625-1631. doi: 10.1002/ptr.5174.
15. Pourhabibi-Zarandi F, Rafrat M, Zayeni H, Asghari-Jafarabadi M, Ebrahimi AA. Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. *Phytother Res* 2022;36(4):1797-1806. doi: 10.1002/ptr.7422.
16. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. *Ann N Y Acad Sci* 2005;1056(1):206-217. doi: 10.1196/annals.1352.010.
17. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med* 1998;64(4):353-356. doi: 10.1055/s-2006-957450.
18. Tabanelli R, Brogi S, Calderone V. Improving Curcumin Bioavailability: Current Strategies and Future Perspectives. *Pharmaceutics* 2021;13(10):1715. doi: 10.3390/pharmaceutics13101715.
19. Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W, Chen H. Efficacy and Safety of Curcumin and *Curcuma longa* Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. *Front Immunol* 2022;13:891822. doi: 10.3389/fimmu.2022.891822.
20. Zheng J, Cheng J, Zheng S, Feng Q, Xiao X. Curcumin, A Polyphenolic Curcuminoid with Its Protective Effects and Molecular Mechanisms in Diabetes and Diabetic Cardiomyopathy. *Front Pharmacol* 2018;9:472. doi: 10.3389/fphar.2018.00472.